

Press release for immediate release

Genomtec's laboratory genetic test detects all variants of SARS-CoV-2 including Omicron

Wrocław, Poland - November 30, 2021. - Genomtec S.A. "GMT," a NewConnect-listed MedTech company specializing in the development of advanced technology in the area of point-of-care (POCT) genetic diagnostics, has conducted an analysis of its rapid genetic tests that confirmed their effectiveness in detecting all known variants of the SARS-CoV-2 virus including the recently discovered Omicron variant.

Due to growing concerns on ability of IVD tests to recognize newly appearing SARS-CoV-2 variants, Genomtec conducted bioinformatic (in-silico) as well as the wet lab analysis of its products, Genomtec® SARS-CoV-2 EvaGreen® RT-LAMP CE-IVD Duo Kit (RT-LAMP Duo) and Genomtec® SARS-CoV-2 EvaGreen® Direct-RT-LAMP CE-IVD Kit (Direct).

Results of the analysis confirmed their reliability in recognition of SARS-CoV-2 variants mentioned on the WHO list, including recently discovered Omicron.

- Recognition of multiple variants by the RT-LAMP Duo and Direct Kit produced by Genomtec is important to ensure public health safety where accurate testing against multiple types of SARS-CoV-2 variants of concern is absolutely crucial in sustaining efforts against pandemic surveillance. – said Miron Tokarski, co-founder and CEO of Genomtec.

More in attached analytical report.

#####

Additional information at:

Genomtec S.A.
Magdalena Kicińska
+48 604 201 230
m.kicinska@genomtec.com

About Genomtec:

Genomtec is an innovative medical technology company dedicated to the development and commercialization of a mobile molecular diagnostics platform for detection of various infectious diseases, and also rapid laboratory diagnostic tests used, among others, in the detection of COVID-19 disease caused by the SARS-CoV-2 virus.

The company's flagship project is the Genomtec ID mobile IVD platform. The analyser is uniquely placed among Point-Of-Care (POC) products worldwide. It will allow for a quick and precise clinical molecular analysis outside the standard laboratory setting, without the need to involve qualified laboratory personnel. The system uses microfluidic technology and the proprietary, patent protected SNAAT® isothermal technology. Appropriate



design of the system enables the process to be carried out in record time, i.e. even in 15 minutes, with the diagnostic parameters equal to, and in some cases exceeding, the quality of PCR laboratory tests.

The development and manufacturing process is executed in close cooperation with international CMO (Contract Manufacturing Organization) companies. According to the assumptions of the Genomtec Management Board, the commercialization of the flagship solution will take place in the first half of 2022.

Manufacturing of Genomtec® SARS-CoV-2 EvaGreen® laboratory tests in RT-LAMP technology is based in Poland, with current EU market authorisation (CE-IVD), and product registration started in other regulatory jurisdictions outside Europe.

Genomtec was founded in 2016. Genomtec SA is headquartered in Wrocław.

More information at: www.genomtec.com Genomtec została założona w 2016 r. Siedziba Spółki Genomtec SA znajduje się we Wrocławiu.

Więcej informacji: www.genomtec.com